Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer

被引：0
|
作者：
Liu, Renyan [1 ]
Pantelidou, Constantia [1 ]
Jadhav, Heta [1 ]
Shapiro, Geoffrey [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5649
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [22] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [23] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [24] Targeting Non-Kinase Function of CDK6 to Overcome CDK4/6 Inhibitor Resistance
    Alluri, P. G.
    Udden, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S44 - S44
  • [25] A kinase inhibitor library screen reveals novel candidates that reverse CDK4/6 inhibitor resistance in CDK6 amplified HR(+) breast cancer
    Lai, Jiun-I
    Zhuang, Yong-Ji
    Lin, Ting-Yi
    Chao, Ta-Chung
    Liu, Chun-Yu
    Tseng, Ling-Ming
    CANCER RESEARCH, 2022, 82 (04)
  • [26] Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer
    Chen, Christopher T.
    Leshchiner, Ignaty
    Martin, Liz
    Kane, Harry
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Gillette, Michael
    Satpathy, Shankha
    Pinto, Christopher
    McLoughlin, Daniel
    Allen, Read
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Carr, Steven
    Parida, Laxmi
    Getz, Gad
    Juric, Dejan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [27] Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
    Lin, Yueh-Te
    Lin, Joseph
    Liu, Yi-En
    Hsu, Kai-Wen
    Hsieh, Chang-Chi
    Chen, Dar-Ren
    Wu, Han-Tsang
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [28] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [29] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [30] CDK4/6 inhibitor-resistant ER plus breast cancer cell lines are hypersensitive to TTK inhibition
    Bretones, Isabel Soria
    Thu, Kelsie L.
    Silvester, Jennifer
    Kiarash, Reza
    Fletcher, Graham C.
    Cruickshank, Jennifer
    Bray, Mark R.
    Mak, Tak W.
    Cescon, David W.
    CANCER RESEARCH, 2020, 80 (04)
12345